In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antabio SAS

www.antabio.com

Latest From Antabio SAS

Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule

With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.

Financing Business Strategies

Appointments: Hikma, Ipsen, PeptiDream, Targovax, Moderna and Perrigo

The latest biopharma industry appointments include C-suite hires at Hikma, Ipsen, Sinclair PeptiDream, Targovax, Nicox, Moderna, Antabio and Perrigo; as well as a supervisory board appointment at Kiadis.

Appointments BioPharmaceutical

Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches

October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.

Financing Commercial

Finance Watch: Canaan Closes New VC Fund; CARB-X Backs More Antibiotics

Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Antabio SAS
  • Senior Management
  • Marc Lemonnier, PhD, CEO
    Gordon Waldron, CFO
    Martin Everett, PhD, CSO
    Magdalena Zalacain, PhD, Head, Preclinical Dev.
    Carole Sable, MD, Head, Clinical Dev.
    Helmuth van Es, CBO
  • Contact Info
  • Antabio SAS
    Phone: (33) 633 34 39 76
    Rue Pierre et Marie Curie
    P.O. Box 28262 Labege, 31682
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register